Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2019 Mar 5:2019:3580941.
doi: 10.1155/2019/3580941. eCollection 2019.

Late-Onset Neutropenia after Rituximab Treatment for Adult-Onset Nephrotic Syndrome

Mayuko Yamazaki  1   2 , Hidekazu Sugiura  1   2 , Yosuke Iwatani  1   2 , Mizuki Kyoda  1   2 , Hirohiko Nokiba  1   2 , Nobuyuki Amemiya  1   2 , Kosaku Nitta  2 , Ken Tsuchiya  2   3
Affiliations
Case Reports

Late-Onset Neutropenia after Rituximab Treatment for Adult-Onset Nephrotic Syndrome

Mayuko Yamazaki et al. Case Rep Nephrol. .

Abstract

A 41-year-old woman developed nephrotic syndrome at the age of 32 and was diagnosed with minimal change nephrotic syndrome based on a renal biopsy. Although remission was achieved with administration of prednisolone (PSL) and cyclosporine, the nephrotic syndrome recurred. She was also started on rituximab (RTX). She developed late-onset neutropenia after RTX treatment (R-LON) and improved 17 days later. Although the majority of R-LON cases undergo spontaneous remission, cases of death have been reported. This report is intended to warn about R-LON, since the use of RTX for adult-onset nephrotic syndrome is expected to increase in the future.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Clinical course. PSL: prednisolone. RTX: rituximab.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Takei T., Iwabuchi Y., Nitta K. Rituximab on steroid-dependent and steroid –resistant nephrotic syndrome in adult. Jin To Touseki (Kidney and Dialysis) 2014;76(1):91–95.
    1. Sugiura H., Takei T., Itabashi M., et al. Effect of single-dose rituximab on primary glomerular diseases. Nephron Clinical Practice. 2011;117(2):c98–c105. doi: 10.1159/000319656. - DOI - PubMed
    1. Iwabuchi Y., Takei T., Moriyama T., Itabashi M., Nitta K. Long-term prognosis of adult patients with steroid-dependent minimal change nephrotic syndrome following rituximab treatment. Medicine (Baltimore) 2014;93:1–7. - PMC - PubMed
    1. Miyabe Y., Takei T., Iwabuchi Y., Moriyama T., Nitta K. Amelioration of the adverse effects of prednisolone by rituximab treatment in adults with steroid-dependent minimal-change nephrotic syndrome. Clinical and Experimental Nephrology. 2016;20(1):103–110. doi: 10.1007/s10157-015-1139-6. - DOI - PubMed
    1. Kabei K., Uchida J., Iwai T., et al. Late-onset neutropenia and acute rejection in ABO-incompatible kidney transplant recipients receiving rituximab and mycophenolate mofetil. Transplant Immunology. 2014;31(2):92–97. doi: 10.1016/j.trim.2014.06.001. - DOI - PubMed

Publication types

LinkOut - more resources